Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludeoxyglucose f-18-M.D. Anderson Cancer Center
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Fludeoxyglucose F-18 is a positron-emitting radiopharmaceutical diagnostic agent produced and distributed by the M.D. Anderson Cancer Center. As a radioactive analog of glucose, it is taken up by cells via glucose transporters (GLUT) and phosphorylated by hexokinase into 18F-FDG-6-phosphate. Because this metabolite cannot be further metabolized in the glycolytic pathway, it accumulates in tissues with high metabolic activity, such as malignant tumors, the brain, and the heart. This accumulation allows for the visualization of altered glucose metabolism using positron emission tomography (PET) imaging. In clinical practice, it is widely used for oncology staging, monitoring treatment response, and detecting recurrence, as well as in neurology and cardiology.
- Brand names
- Fludeoxyglucose F 18 Injection
- Other names
- fludeoxyglucose F-182-deoxy-2-[18F]fluoro-D-glucoseFDG18F-FDG
02
Targets
GLUT1 (Glucose transporter 1)SLC2A2 (Solute carrier family 2 facilitated glucose transporter member 2)SLC2A3 (Glucose transporter type 3)HK2 (Hexokinase Type II)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)GCK (Glucokinase)
Beyond the preview
Go deeper on fludeoxyglucose f-18-M.D. Anderson Cancer Center.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludeoxyglucose f-18-M.D. Anderson Cancer Center.